This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To correlate Mx protein (Mx) levels in lysed blood leukocytes with the clinical response to interferon (IFN) beta-1b (IFNβ-1b) in relapsing–remitting MS (RR-MS) patients for monitoring treatment.
Background: Intracellular Mx expression is exclusively induced by the type I IFNs (IFN-α, -β, and -ω) or by viruses and is strongly increased under IFN treatment. Quantitative determination of Mx allows objective assessment of biological effects of IFN.
Methods: Mx protein levels were measured in blood leukocyte lysates from IFNβ-1b-treated RR-MS patients by ELISA and correlated to clinical parameters, including relapse rate and clinical deterioration.
Results: In stable IFNβ-1b-treated MS patients, Mx levels were significantly increased compared to patients with or without immunosuppressive treatment. In IFNβ-1b-treated MS patients during relapse, Mx levels were significantly lower than during stable phases of the disease. Mean values of Mx (MVMx) over time of treatment in patients with a reduction of relapse rate were significantly higher than in patients without response.
Conclusion: Mx levels in lysed blood cells may represent a useful surrogate marker for IFNβ-1b activity corresponding to the clinical response during treatment of MS.
- Received March 22, 1999.
- Accepted August 4, 1999.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Alert Me
Recommended articles
Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b
Interferon β-1b–neutralizing antibodies 5 years after clinically isolated syndrome
Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b
Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies